All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Bookmark this article
B-cell maturation antigen (BCMA) is a promising target in Multiple Myeloma (MM) and is the current chosen target for numerous MM-directed CAR T-cells, as well as therapeutic monoclonal antibodies – see MM Hub article. However, expression can vary between patients and several studies suggest it has a low target density which further decreases at relapse, thereby potentially escaping therapies and minimizing clinical efficacy.
To address this issue, Lydia Lee and colleagues from the Department of Haematology, UCL Cancer Institute, London, UK, in collaboration with Autolus Ltd, have developed a third generation CAR T-cell construct using the truncated form of a proliferation-inducing ligand (APRIL), the natural ligand for both BCMA and TACI (transmembrane activator and CAML interactor). The resultant construct has been termed ACAR and was tested both in-vitro and in-vivo (with a mouse model). The study was published in Blood in December 2017.
In summary, this study provides a strong rationale for the further clinical investigation of a dual targeting CAR. ACAR displayed target cytolysis at low E: T ratios in vitro and rapid tumor regression in an intramedullary murine myeloma model (48 hours post-ACAR T-cell injection). Additionally, no normal tissue toxicity was observed in vivo and no obvious off-target effects. A-CAR could prove to be especially beneficial for patients with low levels of tumor BCMA, as well as heavily pre-treated patients that may experience antigen down-regulation.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox